tetano
Editor, Senior Moderator
Citation: Wu C-Y, Yeh Y-C, Chan J-T, Yang Y-C, Yang J-R, et al. (2012) A VLP Vaccine Induces Broad-Spectrum Cross-Protective Antibody Immunity against H5N1 and H1N1 Subtypes of Influenza A Virus. PLoS ONE 7(8): e42363. doi:10.1371/journal.pone.0042363
Chia-Ying Wu1, Yi-Chun Yeh1, Jia-Tsrong Chan2, Yu-Chih Yang1, Ji-Rong Yang1,3,4, Ming-Tsan Liu4, Ho-Sheng Wu4, Pei-Wen Hsiao1,3*
1 Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, 2 Genomics Research Center, Academia Sinica, Taipei, Taiwan, 3 Institute of Biotechnology, College of Bio-Resources and Agriculture, National Taiwan University, Taipei, Taiwan, 4 Centers for Disease Control, Department of Health, Taipei, Taiwan
Abstract Top
The recent threats of influenza epidemics and pandemics have prioritized the development of a universal vaccine that offers protection against a wider variety of influenza infections. Here, we demonstrate a genetically modified virus-like particle (VLP) vaccine, referred to as H5M2eN1-VLP, that increased the antigenic content of NA and induced rapid recall of antibody against HA2 after viral infection. As a result, H5M2eN1-VLP vaccination elicited a broad humoral immune response against multiple viral proteins and caused significant protection against homologous RG-14 (H5N1) and heterologous A/California/07/2009 H1N1 (CA/07) and A/PR/8/34 H1N1 (PR8) viral lethal challenges. Moreover, the N1-VLP (lacking HA) induced production of a strong NA antibody that also conferred significant cross protection against H5N1 and heterologous CA/07 but not PR8, suggesting the protection against N1-serotyped viruses can be extended from avian-origin to CA/07 strain isolated in humans, but not to evolutionally distant strains of human-derived. By comparative vaccine study of an HA-based VLP (H5N1-VLP) and NA-based VLPs, we found that H5N1-VLP vaccination induced specific and strong protective antibodies against the HA1 subunit of H5, thus restricting the breadth of cross-protection. In summary, we present a feasible example of direction of VLP vaccine immunity toward NA and HA2, which resulted in cross protection against both seasonal and pandemic influenza strains, that could form the basis for future design of a better universal vaccine.
http://www.plosone.org/article/info...osone/PLoSONE+(PLoS+ONE+Alerts:+New+Articles)
Chia-Ying Wu1, Yi-Chun Yeh1, Jia-Tsrong Chan2, Yu-Chih Yang1, Ji-Rong Yang1,3,4, Ming-Tsan Liu4, Ho-Sheng Wu4, Pei-Wen Hsiao1,3*
1 Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, 2 Genomics Research Center, Academia Sinica, Taipei, Taiwan, 3 Institute of Biotechnology, College of Bio-Resources and Agriculture, National Taiwan University, Taipei, Taiwan, 4 Centers for Disease Control, Department of Health, Taipei, Taiwan
Abstract Top
The recent threats of influenza epidemics and pandemics have prioritized the development of a universal vaccine that offers protection against a wider variety of influenza infections. Here, we demonstrate a genetically modified virus-like particle (VLP) vaccine, referred to as H5M2eN1-VLP, that increased the antigenic content of NA and induced rapid recall of antibody against HA2 after viral infection. As a result, H5M2eN1-VLP vaccination elicited a broad humoral immune response against multiple viral proteins and caused significant protection against homologous RG-14 (H5N1) and heterologous A/California/07/2009 H1N1 (CA/07) and A/PR/8/34 H1N1 (PR8) viral lethal challenges. Moreover, the N1-VLP (lacking HA) induced production of a strong NA antibody that also conferred significant cross protection against H5N1 and heterologous CA/07 but not PR8, suggesting the protection against N1-serotyped viruses can be extended from avian-origin to CA/07 strain isolated in humans, but not to evolutionally distant strains of human-derived. By comparative vaccine study of an HA-based VLP (H5N1-VLP) and NA-based VLPs, we found that H5N1-VLP vaccination induced specific and strong protective antibodies against the HA1 subunit of H5, thus restricting the breadth of cross-protection. In summary, we present a feasible example of direction of VLP vaccine immunity toward NA and HA2, which resulted in cross protection against both seasonal and pandemic influenza strains, that could form the basis for future design of a better universal vaccine.
http://www.plosone.org/article/info...osone/PLoSONE+(PLoS+ONE+Alerts:+New+Articles)